Gene editing system for treating usher syndrome
OwnerYong Sam KIM, Do Yon KIMinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerYong Sam KIM, Do Yon KIMinventors
Estimating the term…
The present invention relates to a gene editing system for treating Usher syndrome, to a disease treatment method using same, and the like, wherein by using the gene editing system of the present invention, an exon 13 region mutated in the Usherin (USH2A) gene is deleted with high efficiency, thereby treating type 2 Usher syndrome effectively. In addition, the gene editing system of the present invention comprises a miniaturized Cas12f1 protein-based endonuclease and an engineered guide RNA having a shorter length and improved indel efficiency, and a carrier having a limited packaging size, such as adeno-associated virus (AAV), can also be used, and therefore, in vivo or intracellular delivery efficiency can also be maximized.
A system for editing a USH2A gene, comprising:
A vector system, comprising at least one vector wherein the at least one vector comprises:
A guide RNA, comprising a spacer region, which comprises a guide sequence capable of hybridizing to a target sequence in a USH2A (Usherin) gene, and a scaffold region, wherein the guide sequence comprises (i) a sequence of contiguous 15 to 22 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.